{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:07:59Z","timestamp":1793729279995,"version":"4.6.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":2962,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.bbmt.2006.10.026","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T07:16:43Z","timestamp":1172042203000},"page":"307-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Pharmacokinetic Disposition and Clinical Outcomes in Infants and Children Receiving Intravenous Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"13","author":[{"given":"Tal","family":"Schechter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulfikarali","family":"Verjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myla","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Lee","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2006.10.026_bib1","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib2","first-page":"18","article-title":"Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens","volume":"20","author":"Grochow","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2006.10.026_bib3","first-page":"31","article-title":"Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.bbmt.2006.10.026_bib5","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.026_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00694339","article-title":"Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation","volume":"25","author":"Grochow","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2006.10.026_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-200039020-00005","article-title":"Plasma concentration monitoring of busulfan: does it improve clinical outcome?","volume":"39","author":"McCune","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bbmt.2006.10.026_bib8","first-page":"759","article-title":"Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?","volume":"14","author":"Schuler","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","volume":"8","author":"Kashyap","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0378-4347(00)84861-6","article-title":"Gas chromatographic determination of busulfan in plasma with electron-capture detection","volume":"277","author":"Hassan","year":"1983","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.bbmt.2006.10.026_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0378-4347(88)80034-3","article-title":"Determination of busulfan in human plasma by gas chromatography with electron-capture detection","volume":"425","author":"Chen","year":"1988","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.bbmt.2006.10.026_bib12","series-title":"Biopharmaceutics and Clinical Pharmacokinetics","author":"Gibaldi","year":"1991"},{"key":"10.1016\/j.bbmt.2006.10.026_bib13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.bmt.1702371","article-title":"An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease","volume":"25","author":"Bolinger","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.bmt.1703612","article-title":"Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"30","author":"McCune","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib15","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2006.10.026_bib16","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","article-title":"Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation","volume":"11","author":"Bearman","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.10.026_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.bmt.1704707","article-title":"Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity","volume":"35","author":"Zwaveling","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00001813-200503000-00014","article-title":"Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation","volume":"16","author":"Oechtering","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bbmt.2006.10.026_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bbmt.2004.07.010","article-title":"Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation","volume":"10","author":"Tran","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/sj.bmt.1704209","article-title":"Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results","volume":"32","author":"Dalle","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2125.2002.01555.x","article-title":"Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation","volume":"53","author":"Cremers","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2006.10.026_bib22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood.V104.11.1151.1151","article-title":"Single daily dose of IV busulfan (BU) in pediatric patients","volume":"104","author":"Kletzel","year":"2004","journal-title":"Blood"},{"issue":"suppl 3","key":"10.1016\/j.bbmt.2006.10.026_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1399-3046.7.s3.2.x","article-title":"Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation","volume":"7","author":"Bostrom","year":"2003","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","article-title":"Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.bmt.1704871","article-title":"Modification of the Bu\/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring","volume":"35","author":"Mamlouk","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/bbmt.2002.v8.pm12374453","article-title":"Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation","volume":"8","author":"Fernandez","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib28","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.bbmt.2004.05.010","article-title":"Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies","volume":"10","author":"Williams","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib29","first-page":"5509","article-title":"Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan","volume":"57","author":"Gibbs","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2006.10.026_bib30","first-page":"52","article-title":"Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro","volume":"26","author":"Gibbs","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bbmt.2006.10.026_bib31","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0090-9556(25)06755-8","article-title":"Liver volume as a determinant of drug clearance in children and adolescents","volume":"23","author":"Murry","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bbmt.2006.10.026_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00280-005-0029-0","article-title":"Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study","volume":"57","author":"Nguyen","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2006.10.026_bib33","first-page":"135","article-title":"Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children","volume":"10","author":"Meresse","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib34","first-page":"467","article-title":"Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome","volume":"7","author":"Ozkaynak","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib35","first-page":"417","article-title":"Optimum dose of busulfan for HSCT in children: yet to be defined","volume":"100","author":"Das","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.026_bib36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.bmt.1704069","article-title":"Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients","volume":"32","author":"Barker","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib37","first-page":"584a","article-title":"Tumor necrosis factor d3 allele predicts for organ dysfunction after allogeneic stem cell transplantation","volume":"96","author":"Haire","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.026_bib38","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/00043426-200212000-00013","article-title":"Hepatic veno-occlusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients","volume":"24","author":"Reiss","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2006.10.026_bib39","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2003-11-3778","article-title":"Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation","volume":"104","author":"Srivastava","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.026_bib40","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.bmt.1701001","article-title":"Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia","volume":"20","author":"Pawlowska","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib41","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.bmt.1704275","article-title":"In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa)","volume":"32","author":"Bouligand","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00688324","article-title":"Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation","volume":"37","author":"Vassal","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2006.10.026_bib43","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.bmt.1703264","article-title":"Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation","volume":"28","author":"Bolinger","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.10.026_bib44","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.026_bib45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-004-0982-4","article-title":"Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation","volume":"84","author":"Lee","year":"2005","journal-title":"Ann Hematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879106007312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879106007312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:29:16Z","timestamp":1761056956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879106007312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1083879106007312"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.10.026","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic Disposition and Clinical Outcomes in Infants and Children Receiving Intravenous Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}